Evoked Potential Monitoring of Vigabatrin Patients
Overview
Pharmacology
Authors
Affiliations
Full-field ERG and visual fields in patients 5 years after discontinuing vigabatrin therapy.
Kjellstrom U, Lovestam-Adrian M, Andreasson S, Ponjavic V Doc Ophthalmol. 2008; 117(2):93-101.
PMID: 18188629 DOI: 10.1007/s10633-007-9108-3.
Examining visual field defects in the paediatric population exposed to vigabatrin.
Spencer E, Harding G Doc Ophthalmol. 2004; 107(3):281-7.
PMID: 14711160 DOI: 10.1023/b:doop.0000005337.39947.83.
Vigabatrin; its effect on the electrophysiology of vision.
Harding G, Robertson K, Spencer E, Holliday I Doc Ophthalmol. 2002; 104(2):213-29.
PMID: 11999628 DOI: 10.1023/a:1014643528474.
Multifocal ERG and full-field ERG in patients on long-term vigabatrin medication.
Ponjavic V, Andreasson S Doc Ophthalmol. 2001; 102(1):63-72.
PMID: 11475366 DOI: 10.1023/a:1017589301855.
Effects of vigabatrin on evoked potentials in epileptic patients.
Cosi V, Callieco R, Galimberti C, Manni R, Tartara A, Mumford J Br J Clin Pharmacol. 1989; 27 Suppl 1:61S-68S.
PMID: 2757911 PMC: 1379681. DOI: 10.1111/j.1365-2125.1989.tb03463.x.